S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
S&P 500   3,977.53 (+0.16%)
DOW   32,432.08 (+0.60%)
QQQ   308.76 (-0.69%)
AAPL   158.28 (-1.23%)
MSFT   276.38 (-1.49%)
META   202.84 (-1.54%)
GOOGL   102.46 (-2.83%)
AMZN   98.04 (-0.09%)
TSLA   191.81 (+0.74%)
NVDA   265.31 (-0.93%)
NIO   8.93 (-1.54%)
BABA   86.12 (-0.90%)
AMD   96.61 (-1.37%)
T   18.87 (+1.40%)
F   11.52 (+0.09%)
MU   59.79 (-2.24%)
CGC   1.88 (-1.05%)
GE   93.31 (+2.12%)
DIS   95.62 (+1.64%)
AMC   4.55 (+1.79%)
PFE   40.22 (-0.42%)
PYPL   73.30 (-0.79%)
NFLX   327.66 (-0.22%)
OTCMKTS:KHTRF

Knight Therapeutics - KHTRF Stock Forecast, Price & News

$3.47
0.00 (0.00%)
(As of 03/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.47
▼
$3.47
50-Day Range
$3.47
▼
$3.96
52-Week Range
$3.47
▼
$4.77
Volume
N/A
Average Volume
2,388 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.08

Knight Therapeutics MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
75.1% Upside
$6.08 Price Target
Short Interest
Bearish
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Knight Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.22 out of 5 stars

See Top Rated MarketRank™ Stocks Here

KHTRF stock logo

About Knight Therapeutics (OTCMKTS:KHTRF) Stock

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its products include ILUVIEN, Nerlynx, Probuphine, Movantik, and Neuragen. The company was founded by Jonathan R. Goodman on November 1, 2013 and is headquartered in Montreal, Canada.

Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KHTRF Stock News Headlines

March 26, 2023 | markets.businessinsider.com
Bloom Burton Keeps Their Buy Rating on Knight Therapeutics (KHTRF)
March 24, 2023 | markets.businessinsider.com
RBC Capital Sticks to Their Buy Rating for Knight Therapeutics (KHTRF)
March 27, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
March 24, 2023 | finance.yahoo.com
G2S2 CAPITAL INC. ANNOUNCES INVESTMENT IN KNIGHT THERAPEUTICS INC.
March 23, 2023 | markets.businessinsider.com
Stifel Nicolaus Remains a Hold on Knight Therapeutics (KHTRF)
January 26, 2023 | finance.yahoo.com
Berkadia Forges Alliance With Knight Frank
December 23, 2022 | marketwatch.com
Knight Therapeutics Closes $38.5 Mln Loan With International Finance Corp.
December 23, 2022 | finance.yahoo.com
Knight Therapeutics Closes US$38.5 million Loan with IFC
March 27, 2023 | Weiss Ratings (Ad)
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
November 13, 2022 | seekingalpha.com
Knight Therapeutics Inc. (KHTRF) Q3 2022 Earnings Call Transcript
November 12, 2022 | finance.yahoo.com
Knight Therapeutics Third Quarter 2022 Earnings: Beats Expectations
November 9, 2022 | finance.yahoo.com
Knight to Present at Stifel Healthcare Conference
November 3, 2022 | finance.yahoo.com
Notice of Knight Therapeutics' Third Quarter 2022 Results Conference Call
August 12, 2022 | seekingalpha.com
Knight Therapeutics' (KHTRF) CEO Samira Sakhia on Q2 2022 Results - Earnings Call Transcript
August 12, 2022 | benzinga.com
G2S2 CAPITAL INC. FILES EARLY WARNING REPORT FOR INVESTMENT IN KNIGHT THERAPEUTICS INC.
July 4, 2022 | nasdaq.com
Knight Therapeutics To Relaunch AKYNZEO In Brazil
June 14, 2022 | finance.yahoo.com
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?
May 24, 2022 | seekingalpha.com
Knight Therapeutics enters license, supply pacts with Rigel
May 12, 2022 | finance.yahoo.com
Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distribution, and Supply Agreement for Akynzeo® and Aloxi®
March 31, 2022 | finance.yahoo.com
Knight Therapeutics Inc. (TSE:GUD) insiders placed bullish bets worth CA$3.1m in the last 12 months
March 25, 2022 | seekingalpha.com
Knight Therapeutics reports Q4 results
March 17, 2022 | finance.yahoo.com
Notice of Knight Therapeutics' Fourth Quarter and Year End 2021 Results Conference Call
January 7, 2022 | nasdaq.com
Knight Therapeutics Inc (KHTRF)
December 14, 2021 | finance.yahoo.com
Is Knight Therapeutics (TSE:GUD) Using Too Much Debt?
December 2, 2021 | finance.yahoo.com
Knight to Present at Stifel GMP’s The Future of Healthcare Conference
November 11, 2021 | finance.yahoo.com
Knight Therapeutics Reports Third Quarter 2021
September 30, 2021 | finance.yahoo.com
What Type Of Shareholders Make Up Knight Therapeutics Inc.'s (TSE:GUD) Share Registry?
See More Headlines
Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KHTRF Company Calendar

Today
3/27/2023
Next Earnings (Estimated)
5/10/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:KHTRF
CUSIP
N/A
CIK
N/A
Web
www.gud-knight.com
Phone
(514) 484-4483
Fax
N/A
Employees
660
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.08
High Stock Price Forecast
$6.75
Low Stock Price Forecast
$5.40
Forecasted Upside/Downside
+75.1%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Samira Sakhia
    President, Chief Executive Officer & Director
  • Utchanah Arvind
    Chief Financial Officer
  • Monica Percario
    Vice President-Global Scientific Affairs
  • Daniela Marino Marino
    Vice President-Legal and Compliance
  • Amal Khouri
    Chief Business Officer

Key Competitors

View All Competitors













KHTRF Stock - Frequently Asked Questions

What is Knight Therapeutics' stock price forecast for 2023?

0 brokers have issued 12 month price objectives for Knight Therapeutics' stock. Their KHTRF share price forecasts range from $5.40 to $6.75. On average, they predict the company's share price to reach $6.08 in the next twelve months. This suggests a possible upside of 75.1% from the stock's current price.
View analysts price targets for KHTRF or view top-rated stocks among Wall Street analysts.

How have KHTRF shares performed in 2023?

Knight Therapeutics' stock was trading at $3.80 at the beginning of 2023. Since then, KHTRF shares have decreased by 8.7% and is now trading at $3.47.
View the best growth stocks for 2023 here.

Are investors shorting Knight Therapeutics?

Knight Therapeutics saw a decrease in short interest in February. As of February 28th, there was short interest totaling 123,500 shares, a decrease of 5.6% from the February 13th total of 130,800 shares. Based on an average daily trading volume, of 6,300 shares, the days-to-cover ratio is currently 19.6 days.
View Knight Therapeutics' Short Interest.

When is Knight Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our KHTRF earnings forecast.

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the OTCMKTS under the ticker symbol "KHTRF."

How do I buy shares of Knight Therapeutics?

Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Knight Therapeutics' stock price today?

One share of KHTRF stock can currently be purchased for approximately $3.47.

How many employees does Knight Therapeutics have?

The company employs 660 workers across the globe.

How can I contact Knight Therapeutics?

Knight Therapeutics' mailing address is 3400 de Maisonneuve West, Montréal, QC H3Z. The official website for the company is www.gud-knight.com. The company can be reached via phone at (514) 484-4483.

This page (OTCMKTS:KHTRF) was last updated on 3/27/2023 by MarketBeat.com Staff